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The Gag protein of human immunodeficiency virus type 1 (HIV-1) contains a 14-amino-acid region termed SP1 that is located between
the capsid (CA) and nucleocapsid (NC) domains. It has been previously observed that either a M368A substitution within SP1 or the DSP1
deletion impaired virus production. In this study, we further showed that the M368A point mutation, but not the DSP1 deletion, severely
diminished the levels of membrane-associated Gag proteins. This membrane binding defect associated with M368A was corrected either by
changing NC to the leucine zipper (LZ) motif derived from the yeast transcription factor GCN4 or by a L364A second-site mutation in the
context of the first four residues of SP1. Yet, neither the L364A mutation nor the LZ substitution restored wild type levels of particle
production to the M368A Gag. These results suggest that SP1 affects both Gag–membrane binding and the subsequent events of virus
assembly such as capsid morphogenesis or virus budding.
D 2005 Elsevier Inc. All rights reserved.
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Human immunodeficiency virus type 1 (HIV-1) encodes a
Gag protein that drives the formation of virus particles on the
plasma membrane (Gheysen et al., 1989). During or shortly
after virus budding, Gag is cleaved by viral protease giving
rise to mature structural proteins such as matrix (MA), capsid
(CA), nucleocapsid (NC), p6, as well as short peptides SP1
and SP2. This proteolysis event results in the transformation
of virus particle from an immature to a mature form.
Each of the MA, CA, NC, and p6 domains plays distinct
roles in Gag assembly. The N-terminal region of MA
composes the membrane binding (M) domain that targets
Gag to the plasma membrane for assembly (Spearman et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.03.004
T Corresponding author. Fax: +1 514 340 7537.
E-mail address: chen.liang@mcgill.ca (C. Liang).1994; Zhou et al., 1994). The M domain consists of a
myristyl moiety that is covalently attached to a glycine that
anchors Gag to the lipid bilayer as well as a group of basic
amino acids that further stabilize Gag–membrane associa-
tion through electrostatic interaction with the negatively
charged phosphate groups (Gottlinger et al., 1989; Hill et
al., 1996; Spearman et al., 1994; Zhou and Resh, 1996;
Zhou et al., 1994). MA molecules are observed to form
trimers under certain conditions and this activity of MA may
contribute to Gag multimerization (Hill et al., 1996). CA
folds into two independent domains, named the N-terminal
domain (NTD) and the C-terminal domain (CTD) (Berthet-
Colominas et al., 1999; Gamble et al., 1996, 1997; Momany
et al., 1996). Multimerization of CA leads to the formation
of a hexagonal lattice, a principle that regulates the gene-
ration of mature conical core and, possibly, the immature
capsid as well (Ganser et al., 1999; Li et al., 2000; Mayo et
al., 2002, 2003). NC is highly basic and exhibits strong05) 232–241
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Campbell and Rein, 1999; Campbell and Vogt, 1995;
Cimarelli et al., 2000; Khorchid et al., 2002; Sandefur et
al., 2000; Zhang et al., 1998). This property allows NC to
promote Gag gathering through the use of RNA as a
scaffold. Accordingly, NC is termed the interaction (I)
domain. P6 resides at the C-terminus of Gag and contains a
tetrapeptide motif bPTAPQ that functions as a late budding
(L) domain (Gottlinger et al., 1991; Huang et al., 1995). The
L domain recruits a cellular factor TSG101 (tumor sus-
ceptibility gene 101) to the virus assembly site. Together
with other cellular factors such as AIP1, TSG101 stimulates
virus release from cells (Freed, 2002; Garrus et al., 2001;
Martin-Serrano et al., 2001; Strack et al., 2003; VerPlank et
al., 2001; von Schwedler et al., 2003).
Aside from the aforementioned domains of Gag, the 14-
amino-acid SP1 region, located between CA and NC, is
indispensable for virus production. For instance, deletion of
SP1 virtually abolishes HIV-1 production (Krausslich et al.,
1995). Results of computer modeling reveal that SP1 is
involved in the formation of a putative a-helix that spans the
CA–SP1 junction (Accola et al., 1998). Importance of this
putative 13-amino-acid helical structure in HIV-1 replication
is supported by the following evidence. First, insertion of
either glycine or proline residue into this helical region
abrogates virus production (Accola et al., 1998; Liang et al.,
2002). Second, 6 amino acids within this helix are identified
as key residues for generation of virus particles (Liang et al.,
2002; Melamed et al., 2004). It is thus conceived that SP1
acts together with the upstream CA sequence to regulate the
assembly activity of Gag precursor. However, a detailed
appreciation of the mechanisms for this function of SP1 is
hampered by the observation that SP1 is highly flexible in
the context of either the upstream CA or the downstream
NC domain, as shown by the results of crystal structural
analysis and nuclear magnetic resonance experiments
(Newman et al., 2004; Worthylake et al., 1999).
In this study, we have assessed the effects of two SP1
mutations on the ability of HIV-1 Gag to associate with
cellular membranes such as to understand the potential
involvement of SP1 in this important step during Gag
assembly. The results showed that the M368A point
mutation but not the DSP1 deletion led to severely
decreased levels of membrane-associated Gag proteins,
even though both mutations impaired virus production to
similar extents.Results
The M368A point mutation within the SP1 region
suppresses Gag–membrane binding in the context of the NC
sequence
We have previously shown that the M368A point
mutation within SP1 inhibited HIV-1 production (Liang etal., 2002) (Fig. 1A). Results of further analysis indicate that
the M368A Gag is severely defective in binding to cellular
membranes, which, at least partially, causes impairment in
virus production (Guo et al., 2005). In this study, we first
tested the effect of M368A on the membrane binding ability
of a truncated Gag protein named MA/CA/SP1 that lacks
the NC/SP2/p6 sequences (Fig. 1A). This Gag derivative
associates with cellular membranes at levels similar to the
full-length Gag, as shown by the results of membrane
flotation experiments (Fig. 1B) (Ono and Freed, 2001).
Surprisingly, in contrast to its negative impact on membrane
binding seen for the full-length Gag protein, the M368A
mutation did not affect the MA/CA/SP1 Gag in this respect
(Fig. 1B). This observation suggests that only in the context
of the sequences downstream of SP1 (such as NC) does the
M368A mutation restrict Gag–membrane association.
To test this idea, we changed the NC sequence to a 34-
amino-acid leucine zipper (LZ) motif that has been shown to
support HIV production in the place of NC (Fig. 1A)
(Accola et al., 2000). When the M368A mutation and LZ
substitution were engineered into the same Gag molecule,
the resultant M368A-LZ Gag mutant displayed wild type
levels of membrane binding (Fig. 1B). More importantly,
the M368A-LZ Gag produced virus particles at levels higher
than the M368A Gag, albeit still markedly lower than wild
type (Fig. 1C). These data indicate that M368A may disrupt
the assembly activity of NC and thus impede Gag–
membrane binding in an indirect manner.
Deletion of SP1 does not affect Gag–membrane binding
Gag protein lacking the SP1 region is defective in particle
production (Krausslich et al., 1995). Yet, results of electron
microscopy reveal electron-dense layers of Gag proteins
beneath the plasma membrane, indicating an efficient
membrane binding for the DSP1 Gag (Krausslich et al.,
1995). Consistent with this observation, results of membrane
flotation assays showed that the DSP1 Gag bound cellular
membranes at wild type levels (Fig. 2). A simple explanation
for the opposingmembrane-binding activities associated with
the M368A and DSP1 Gag proteins is that, when SP1 is
deleted, the N-terminal sequence of NC sequence takes over
the place as well as the functions of SP1 and, as a result, helps
to restore membrane binding to the DSP1 Gag. Were this the
case, mutation of these N-terminal residues of NC in the
context of the DSP1 Gag should decrease Gag–membrane
association to an extent similar to that caused by the M368A
mutation. However, none of the five NC point mutations
tested, that is, M379A, Q380A, R381A, G382A and N383A,
reduced the levels of membrane-associated DSP1 Gag (Fig.
2). One interpretation of this latter result is that the SP1
sequence does not play a direct role in promoting Gag–
membrane association. In the context of this perception, the
negative role for M368A mutation in Gag–membrane
association is likely a result of its deleterious effect on the
other activities of Gag such as multimerization.
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type but not the DSP1 Gag
We have previously identified a L364A point mutation
that is located at the CA–SP1 junction and eliminated virus
production (Liang et al., 2002). The results of membraneflotation experiments showed that L364A markedly reduced
the levels of membrane-bound Gag proteins (Figs. 3A, B).
Consistently, the results of confocal microscopy revealed that
the L364A Gag exhibited dispersed distribution within the
cytoplasm as opposed to the punctate plasma membrane-
associated distribution seen for the wild type Gag (Fig. 3C).
Fig. 2. The DSP1 Gag binds cellular membranes at wild type levels. (A) Depiction of Gag mutants lacking the SP1 sequence. The substituted NC residues were
underlined. (B) Membrane binding ability of various Gag derivatives measured by membrane flotation experiments. The top gel panel showed the expression of
various Gag mutants within transfected COS-7 cells.
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deletion, the resultant L364A-DSP1 Gag-bound cellular
membranes at levels similar to those of either the wild type
or DSP1 Gag proteins as shown by the results of both
membrane flotation experiments and confocal microscopy
(Figs. 3A, B, C). It is thus concluded that the negative impact
of L364A on Gag–membrane binding occurs only in the
context of SP1 sequence. To test this notion, we tried to
identify the key SP1 sequence that is involved in this negative
activity of L364A. Accordingly, three DNA constructs were
engineered that contained each of the 365-AE-366, 365-
AEAM-368 and 365-AEAMSQVT-372 sequences derived
from the N-terminal portion of SP1 (Fig. 3A). The results ofFig. 1. Effects of the M368A mutation on Gag–membrane association. (A) Schema
HIV-1 wild type (WT) Gag precursor. Amino acid sequence across the CA–SP1–
asterisks. Gag–LZ contains the leucine zipper (LZ) motif from the yeast transcripti
the NC/SP2/p6 sequences. All Gag mutations were engineered into BH10-PR co
the first methionine of MA. (B) Membrane binding ability of the wild type a
Transfected COS-7 cells were lysed by dounce homogenization prior to membrane
aliquot of the cell lysates prior to flotation centrifugation was examined in Western
Eight fractions were collected from each gradient and levels of Gag were measure
bound Gag was determined as a percentage of the total Gag amount across the
independent experiments. (C) Virus production by the wild type and mutated Gag
Levels of Gag proteins associated with cells and virus particles were assessed by
generated by each DNA construct were calculated on the basis of virus particle-aFig. 3B show that the L364A-SP1(4) and L364A-SP1(8) Gag
proteins but not L364A-SP1(2) were defective in membrane
binding. Therefore, the L364Amutation acts in the context of
the first four amino acids 365-AEAM-368 of SP1 to restrict
Gag–membrane association.
Defective membrane binding of the M368A Gag is corrected
by the L364A second-site mutation
Of note, the L364 and M368 residues belong to a short
motif 364-LAEAM-368 and both affect Gag–membrane
association. We speculated that these two amino acids,
containing long hydrophobic side chains, might act in atic illustration of various Gag derivatives. On the top is a domain structure of
NC junctions is shown in which the protease cleavage sites are denoted by
on factor GCN4 in the place of NC (Accola et al., 2000). MA/CA/SP1 lacks
ntaining a D25A mutation in protease. Number of the amino acids refers to
nd mutated Gag proteins measured by membrane flotation experiments.
flotation centrifugation through a 10%/65%/73% sucrose step gradient. An
blots for Gag expression and the results were included as the top gel panel.
d by Western blot using anti-p24 antibody. The relative level of membrane-
eight fractions in each gradient. The data shown are the average of three
proteins. COS-7 cells were transfected with various Gag DNA constructs.
Western blot using anti-p24 antibody. The relative levels of virus particles
ssociated p24 values with those of the wild type set at 100.
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test this speculation, both L364 and M368 were changed to
an alanine that harbors a short side chain. The results of
membrane flotation experiments showed that the L364A/
M368A-SP1(4) Gag exhibited significantly higher levels of
membrane binding as compared with L364A-SP1(4) and
M368A-SP1(4) Gag (Figs. 3A, B). In support of the
biochemical data, the L364A/M368A-SP1(4) Gag, but
neither the L364A-SP1(4) nor M368A-SP1(4) Gag, was
observed to localize on plasma membranes as shown by the
results of confocal microscopy (Fig. 3C). Yet, the L364A/
M368A-SP1(4) Gag remained defective in virus production
(Fig. 3D), likely because amino acids 364A and 368A areFig. 3. A synergistic effect of the L364 and M368 residues on Gag–membrane bind
of the SP1 sequence. The substituted amino acids were underlined. (B) Levels of m
gel panel indicated the expression levels of various Gag mutants in transfected CO
including DSP1, L364ADSP1, SP1(4), L364A-SP1(4), M368A-SP1(4) and L36
terminus of Gag and the distribution of Gag-GFP was visualized with laser-sc
phenotypes. (D) Virus production by the L364A/M368A-SP1(4) and L364A-DSPunable to recreate the Gag–Gag interactions that are
mediated by wild type L364 and M368.
The membrane-bound DSP1 Gag complex is sensitive to the
treatment by Brij98
The DSP1 Gag associated with cellular membranes at
almost wild type levels, yet was severely deficient in virus
production. This result implicates that the DSP1 Gag may
bind membrane in an aberrant manner in comparison to the
wild type Gag. To obtain insight into this hypothetical
defect, the Gag–membrane complex was exposed to 0.5%
Brij98 prior to flotation centrifugation. Consistent with theing. (A) Schematic illustration of the L364A mutation and various deletions
embrane-bound Gag proteins measured by flotation centrifugation. The top
S-7 cells. (C) Subcellular distribution of the wild type Gag and Gag mutants
4A/M368A-SP1(4). Green fluorescent protein (GFP) was linked to the C-
anning confocal microscopy. The images shown represent the prevalent
1 Gag mutants.
Fig. 3 (continued ).
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of the wild type Gag proteins were membrane-bound after
Brij98 extraction (Fig. 4). In contrast, the vast majority ofFig. 4. Brij98 extraction dissociates the DSP1 but not the wild type Gag
from cellular membranes. The membrane-bound Gag complex was first
collected from the 10%/65% sucrose interface following the first round of
flotation centrifugation, and then incubated at 37 8C for 5 min either in the
presence or absence of 0.5% Brij98. The treated samples were subjected to
a second round of flotation centrifugation. Distribution of Gag proteins
within each gradient was assessed by Western blot using anti-p24 antibody.the DSP1 Gag was unable to float to the 10%/65% sucrose
interface following such a treatment (Fig. 4). This obser-
vation indicates that the DSP1 Gag associates with cellular
membranes that can be solubilized by Brij98 at 37 8C,
whereas the wild type Gag binds Brij98-resistant membrane
domains. Alternatively, the DSP1 Gag may form a loose
complex on the membranes due to lowered multimerization
ability in comparison to a compact membrane-associated
complex formed by the wild type Gag.Discussion
In this study, we observed that the M368A mutation led
to decreased Gag–membrane association. Since Gag–mem-
brane binding is controlled by the M domain that is located
at the N-terminus of MA (Spearman et al., 1994; Zhou et al.,
1994), it is unlikely that the M368A mutation, which resides
far downstream of MA, affects the function of M domain in
a direct fashion. Rather, M368A mutation may compromise
X. Guo, C. Liang / Virology 335 (2005) 232–241238Gag multimerization and, as a result, restrict Gag–mem-
brane binding. This speculation is in line with the bmyristyl
switchQ model, which describes that Gag multimerization
triggers the exposure of the myristyl group at the N-
terminus of MA and thus increases the affinity of Gag for
cellular membranes (Hermida-Matsumoto and Resh, 1999;
Paillart and Gottlinger, 1999; Spearman et al., 1997; Tang et
al., 2004; Zhou and Resh, 1996).
The crippled membrane binding observed forM368AGag
is corrected by replacing NC with leucine zipper sequence
(Fig. 1B). This is likely due to the different means that NC
and leucine zipper employ to mediate Gag–Gag interactions.
NC binds to RNA and exploits RNA as a scaffold to gather
Gag molecules, whereas leucine zipper motif induces
protein–protein association by forming a dimer structure. In
contrast to the homogeneous dimer structure formed by
leucine zipper, NC adopts different conformations when it
binds to different RNA sequences (Amarasinghe et al., 2000;
De Guzman et al., 1998). An immediate consequence of this
adaptive NC–RNA interaction is the requirement for a
mechanism to align the NC–RNA complexes of diverse
conformations with the rigid hexagonal lattice formed by the
upstream CA domain in order to generate the compact
immature capsid structure. The SP1 sequence, located
between CA and NC, is expected to play such a role. In the
context of this hypothesis, the M368A mutation may impair
this function of SP1 and thus compromise Gag multi-
merization. With leucine zipper motif in the place of NC,
the CA lattice and the LZ dimer can be readily packed into
one complex even in the presence of the M368A mutation.
As a result, the M368A-LZ Gag is able to multimerize to an
extent that suffices for Gag–membrane association.
Our results show that the M368A mutation was also
compensated by the L364A second-site mutation in the
context of the first four amino acids of SP1 with respect to
the rescue of defective membrane binding (Fig. 3B). Either
L364A or M368A restricts Gag–membrane association, yet
a combination of the two corrects this defect. This indicates
that L364 and M368, which are closely located, may
together coordinate one motif that is vital for the functions
of Gag. Within the putative helical structure across the CA–
SP1 junction, L364 and M368 reside on the same side of the
helix surface and thus are able to mediate hydrophobic
interactions between Gag molecules in a synergistic manner
(Accola et al., 1998). When either of these two amino acids
is changed to an alanine, this hydrophobic synergy is
disturbed and, as a result, SP1 is unable to act properly to
promote Gag multimerization. On the other hand, a weak
hydrophobic synergy may be recreated when both L364 and
M368 are changed to alanine and consequently, the function
of SP1 is partially restored.
It is interesting to note that the M368A point mutation
impairs Gag–membrane association whereas the DSP1
deletion does not. One explanation for this observed
difference is that these two mutations exert different impacts
on the local structure of the CA–SP1 junction. Indeed,results of secondary structure modeling indicate that the
M368A mutation does not change the probability for the
CA–SP1 boundary sequence to adopt an a-helix; in
contrast, deletion of the SP1 region leads to the formation
of an extended structure instead of a helix by the newly
created CA–NC junction sequence (data not shown). We
propose that the M368A mutation disrupts protein–protein
interactions that are mediated by the CA–SP1 helix and thus
abrogates Gag multimerization as well as Gag–membrane
binding. On the other hand, the extended CA–NC structure
in the absence of SP1 may form a new type of Gag–Gag
interaction that, though different from that mediated by the
CA–SP1 helical structure, still permits Gag to multimerize
and to associate with membranes, yet does not suffice for
the generation of particles.
In summary, the M368A point mutation and the DSP1
deletion impair HIV-1 production by affecting different
stages of Gag assembly. M368A restricts Gag–membrane
association, whereas deletion of SP1 affects a step post
Gag–membrane binding. Although defective membrane
binding for the M368A Gag can be corrected by second-
site mutations, the resulting recombinant Gag proteins
remain deficient in particle production, implicating multiple
defects caused by M368A.Materials and methods
Plasmid construction
The HIV-1 proviral DNA clone BH10 was employed as
the starting material for the following mutagenesis experi-
ments. DNA constructs MA/CA/SP1 contains a stop codon
at the C-terminus of SP1. This stop codon was inserted into
BH10 by PCR through use of primers SP1-S (5V-CAGC-
TACCATAATGT AGCAGAGAGGCAATTTTAGG-3V)/
NC-A (5V-TTAGCCTGTCTCTCAGTACAATC-3V) as well
as BH10 as DNA template. The PCR products were then
employed as mega-primers for the second round of PCR
together with a sense primer Sph-S (5V-AGTGCA TCCAGT-
GATGCAGGGCC-3V). The final PCR products were
digested with restriction enzymes SphI and ApaI and
inserted into BH10-PR containing a D25A mutation in
the protease region (Morin et al., 1998).
The same strategy was exploited to generate the
following DNA constructs DSP1, DSP1-M379A, DSP1-
Q380A, DSP1-R381A, DSP1-G382A, DSP1-N383A,
L364A-DSP1, L364A-SP1(2), L364A-SP1(4), L364A-
SP1(8), L364A/M368A-SP1(4), M368A-SP1(4), and
SP1(4). The relevant primers are as follows:
DSP1: 5V-GGGAGTAGGAGGACCCGGCCATAAGG-
CAAGAGTTTTGATGCAGAGAGGC AATTTTAG-
GAACC-3V,
DSP1-M379A: 5V-GGCAAGAGTTTTGGCGCAGA-
GAGGCAATTTTAGG-3V,
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GAGGCAATTTTAGG-3V,
DSP1-R381A: 5V-GAGTTTTGATGCAGGCAGG-
CAATTTTAGGAACC-3V,
DSP1-G382A: 5V-GAGTTTTGATGCAGAGAGC-
CAATTTTAGGAACC-3V,
DSP1-N383A: 5V-GTTTTGATGCAGAGAGGCGCTTT-
TAGGAACCAAAG-3V,
L364A-DSP1: 5V-CATAAGGCAAGAGTTGCGATG-
CAGAGAGGC-3V.
L364A-SP1(2): 5 V-GTAGGAGGACCCGGCCA-
TAAGGCAAGAGTTGCGGCTGAAATGCAGA-
GAGGCAATTTTAGG-3V,
L364A-SP1(4): 5V-GGACCCGGCCATAAGGCAA-
GAGTTGCGGCTGAAGCAATGATGCAGAGAGG-
CAATTTTAGG-3V,
L364A-SP1(8): 5V-GGCAAGAGTTGCGGCTGAAG-
CAATGAGCCAAGTAACAATGCAGAGAGG-
CAATTTTAGG-3V,
L364A/M368A-SP1(4): 5V-GGCCATAAGGCAA-
GAGTTGCGGCTGAAGCAGCGATGCAGAGAGG-
CAATTTTAGG-3V.
M368A-SP1(4): 5V-GGACCCGGCCATAAGGCAA-
GAGTTTTGGCTGAAGCAGCGATGCAGAGAGG-
CAATTTTAGG-3V
SP 1 ( 4 ) : 5 V- GGACCCGGCCATAAGGCAA -
GAGTTTTGGCTGAAGCAATGATGCAGAGAGG-
CAATTTTAGG-3V
The Gag–LZ DNA construct contains the leucine zipper
domain of yeast transcription factor GCN4 in the place of
NC and was generated as described in the following. The
Gag sequence 379–406 was first removed by PCR using
primers Sph-S/NC-L (5V-TCC TAGGGGCCCCATTATGG-
TAGCTGAATTTGTTAC-3V). The PCR products were
digested with SphI and ApaI and inserted into BH10-PR.
To further remove Gag sequence 409–423, a second PCR
was conducted with primers NC-R (5V-CACGGT GGG
CCCCTAGGATCTAGAGGGAAGATCTGGCCTTCC-
TAC-3V)/Sal-A (5V-GCCTAA TCCGCTATGTCGACACC-
CAATTCT-3V). An XbaI restriction site was inserted
downstream of ApaI site in order to insert the leucine
zipper sequence into Gag. The PCR products were inserted
into BH10-PR following digestion with ApaI and SalI and
the resultant DNA construct was named DNC. The 36-
amino acid leucine zipper sequence, as previously described
(Accola et al., 2000), was amplified using primers LZ-S(5V-
GCACACGGGCCCATGAAGCAGCTCGAGG-3V)/LZ-
A(5V-CACGG TTCTAGACTCACCCACAAGC-3V) and
inserted into DNC to generate DNA construct Gag–LZ.
All primers were purchased from Invitrogen (Burlington,
ON, Canada).
The Gag–GFP fusion protein was generated as pre-
viously described (Guo et al., 2004). DNA constructs
SP1(4)-GFP, DSP1-L364A-GFP, L364A-SP1(4)-GFP,
M368A-SP1(4)-GFP and L364A/M368A-SP1(4)-GFP werecreated by PCR through use of the Sph-S/NC-A primer pair
and the HIV-1 cDNA containing the relevant Gag mutations
as DNA templates. Amplified fragments were cloned into
the Gag-GFP DNA following digestion with SphI and
ApaI.
Cell culture and transfection
COS-7 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum. Transfection was performed using Lipofect-
amine (Invitrogen) in accordance with the manufacturer’s
instructions.
Membrane flotation centrifugation
These experiments were performed as described (Ono
and Freed, 1999). In brief, transfected COS-7 cells were
washed three times with cold phosphate-buffered saline and
suspended in ice-cold TNE buffer containing 50 mM Tris–
HCl [pH 7.4], 150 mM NaCl, 2 mM EDTA, 0.1% 2-
mercaptoethanol and protease inhibitor cocktails (Roche
Diagnostics, Laval, QC, Canada). After Dounce homoge-
nization on ice, cell homogenates were clarified at 3000
rpm for 30 min at 4 8C in a Beckman GS-6R centrifuge to
remove cell debris and nuclei. The supernatants were
adjusted to 73% sucrose and loaded at the bottom of the
ultracentrifuge tube. After being layered with 65% and
10% sucrose solution, the samples were centrifuged at
100,000  g for 16 h at 4 8C. Eight fractions were then
collected from the top of the tube and the membrane-
associated materials at the 10%/65% interface was
collected in fraction 2.
Immunoblots
Samples were fractionated on SDS-10% polyacrylamide
gels. After proteins were transferred onto PVDF membranes
(Roche), Western blots were performed using mouse anti-
p24 antibody (ID Labs Inc., London, ON, Canada).
Confocal microscopy
COS-7 cells were transfected with the wild type or
mutated Gag-GFP DNA followed by fixation in 4%
paraformaldehyde (in phosphate-buffered saline) at room
temperature for 20 min. After washing with phosphate-
buffered saline, cells were directly visualized using a Zeiss
LSM 5 PASCAL laser-scanning confocal microscope.Acknowledgments
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